Discuss This Drug

trastuzumab-anns

CHEBI:CHEBI_750556

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2257300
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
route
INTRAVENOUS
marketing_category
BLA
nui
N0000020008
pharm_class_epc
HER2/neu Receptor Antagonist [EPC]
pharm_class
HER2/Neu/cerbB2 Antagonists [MoA]
pharm_class_moa
HER2/Neu/cerbB2 Antagonists [MoA]
marketing_start_date
20191028
package_marketing_start_date
20191028
unii
P188ANX8CK
labeler_name
Amgen Inc
manufacturer_name
Amgen Inc
generic_name
trastuzumab-anns
brand_name
Kanjinti
brand_name_base
Kanjinti
product_ndc
55513-164
application_number
BLA761073
spl_id
d5b76373-d6e0-4842-b882-8709ad511807
active_ingredient_name
TRASTUZUMAB
active_ingredient_strength
150 mg/7.15mL
package_ndc
55513-164-01
package_description
1 KIT in 1 CARTON (55513-164-01) * 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01) / 20 mL in 1 VIAL, MULTI-DOSE * 20 mL in 1 VIAL (55513-152-01)
spl_set_id
9a94f5b2-b84e-4987-8ea1-c4346db5a5fa
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class